Bristlecone Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-2,779
| Closed | -$379K | – | 386 |
|
|
2024
Q4 | $379K | Sell |
2,779
-76
| -3% | -$10.4K | 0.03% | 218 |
|
|
2024
Q3 | $329K | Sell |
2,855
-30
| -1% | -$3.46K | 0.03% | 231 |
|
|
2024
Q2 | $397K | Sell |
2,885
-95
| -3% | -$13.1K | 0.03% | 201 |
|
|
2024
Q1 | $411K | Sell |
2,980
-15
| -0.5% | -$2.07K | 0.04% | 199 |
|
|
2023
Q4 | $395K | Sell |
2,995
-154
| -5% | -$20.3K | 0.04% | 199 |
|
|
2023
Q3 | $354K | Hold |
3,149
| – | – | 0.04% | 195 |
|
|
2023
Q2 | $297K | Sell |
3,149
-292
| -8% | -$27.5K | 0.03% | 220 |
|
|
2023
Q1 | $348K | Sell |
3,441
-251
| -7% | -$25.4K | 0.04% | 203 |
|
|
2022
Q4 | $441K | Hold |
3,692
| – | – | 0.05% | 184 |
|
|
2022
Q3 | $392K | Buy |
3,692
+32
| +0.9% | +$3.4K | 0.05% | 181 |
|
|
2022
Q2 | $357K | Sell |
3,660
-2,189
| -37% | -$214K | 0.04% | 192 |
|
|
2022
Q1 | $548K | Buy |
5,849
+898
| +18% | +$84.1K | 0.07% | 152 |
|
|
2021
Q4 | $422K | Buy |
4,951
+1,181
| +31% | +$101K | 0.05% | 172 |
|
|
2021
Q3 | $362K | Buy |
3,770
+444
| +13% | +$42.6K | 0.05% | 170 |
|
|
2021
Q2 | $324K | Buy |
3,326
+85
| +3% | +$8.28K | 0.04% | 175 |
|
|
2021
Q1 | $315K | Buy |
3,241
+675
| +26% | +$65.6K | 0.05% | 176 |
|
|
2020
Q4 | $246K | Buy |
+2,566
| New | +$246K | 0.04% | 183 |
|